Company news: Cadila Healthcare

| Updated on July 12, 2018 Published on July 12, 2018

Zydus Hospira Oncology Pvt Ltd, a 50:50 joint venture company between Zydus Cadila and Hospira Inc, US (now part of Pfizer Group), has received an establishment inspection report (EIR) from the USFDA. The US authority has concluded that the inspection is closed, stating that the inspection classification of this facility is ‘Voluntary Action Indicated’. The manufacturing plant had conducted the USFDA audit from April 5 to 12. Shares of Cadila Healthcare slipped 1.3 per cent at ₹366.70 on the BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on July 12, 2018
This article is closed for comments.
Please Email the Editor